Why in news?
The international NeoSep1 antibiotic trial expanded to India, and JIPMER in Puducherry recruited India’s first participating baby. A second infant joined at PGIMS Rohtak, and the study will compare treatments for drug-resistant neonatal sepsis.
Background
A neonate is a baby during the first 28 completed days after birth. This period carries special health risks.
A newborn immune system is still developing, and premature and low-birth-weight babies face even greater infection risk.
Sepsis is life-threatening organ dysfunction caused by an abnormal response to infection. The body’s own response begins damaging organs.
Neonatal sepsis therefore means sepsis during the neonatal period. Some studies include young infants up to 60 or 90 days.
Age distinction: “Under 90 days” describes a broader young-infant group, and the strict neonatal period ends after 28 completed days.
How does neonatal sepsis begin?
Bacteria are the most common cause, and viruses and fungi can also cause severe newborn infection.
Microbes may enter before, during or after birth, and the timing helps doctors identify likely sources.
Early-onset and late-onset sepsis
- Early-onset sepsis commonly appears within the first 72 hours.
- It often follows exposure to organisms from the mother around delivery; Late-onset sepsis appears after the early period.
- It may come from hospitals, caregivers or the surrounding community.
Definitions vary slightly across clinical guidelines, and the 72-hour division is common in neonatal research.
Important risk factors
- Premature birth reduces immune and skin-barrier development, and low birth weight increases vulnerability to severe infection.
- Prolonged rupture of membranes may increase early infection risk, and invasive tubes and intravenous lines can provide entry routes.
- Long hospital stays increase exposure to resistant organisms, and poor hand hygiene can spread infection between patients.
Possible warning signs
Newborns may not show a clear fever, and their signs can be mild and non-specific.
- The baby may feed poorly or stop sucking, and movement may decrease and unusual sleepiness may appear.
- Body temperature may become high or abnormally low, and breathing may become fast, slow or irregular.
- Heart rate and blood pressure may change, and vomiting, abdominal swelling, jaundice or seizures may occur.
These signs require urgent medical assessment, and delay can allow rapid organ damage.
Diagnosis and immediate treatment
Doctors examine the baby and collect blood for culture, and a culture can identify the organism and useful antibiotics.
Culture results take time, and doctors therefore begin empirical antibiotics when sepsis is strongly suspected.
Empirical treatment means acting before the exact organism is known, and treatment can later change after laboratory results.
Supportive care may include oxygen, fluids, temperature control and feeding assistance, and treatment must occur in a properly equipped hospital.
Why is antimicrobial resistance dangerous here?
Antimicrobial resistance allows microbes to survive medicines that once killed them, and resistant bacteria can make standard combinations ineffective.
Doctors may then use expensive or toxic last-resort antibiotics, and evidence for newborn doses is often limited.
Newborn bodies process medicines differently from adults, and adult trial results cannot simply determine a newborn dose.
What is NeoSep1?
NeoSep1 is an international clinical trial sponsored by the Global Antibiotic Research and Development Partnership. GARDP is a Swiss not-for-profit organisation.
The trial began in South Africa and Kenya during 2023, and it later expanded across Africa and Asia.
The study plans to enrol around 3,000 newborns. It compares several existing antibiotic combinations rather than waiting for entirely new medicines.
Treatments being studied
- Fosfomycin with amikacin forms one study combination, and flomoxef with amikacin forms another combination.
- Flomoxef with fosfomycin forms a third combination, and other accepted local regimens provide comparison groups.
Earlier work validated newborn doses for fosfomycin and flomoxef, and both are older antibiotics with potential value against resistant bacteria.
What is the PRACTical design?
NeoSep1 uses a Personalised Randomised Controlled Trial design, and its short name is PRACTical.
The design compares several treatments across hospitals with different resistance patterns. It can rank which options work best in each setting.
The main outcome is death within 28 days, and other outcomes include hospital stay, treatment changes and later readmission.
Indian study sites
- Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) recruited India’s first participant.
- Pt. B. D. Sharma Post Graduate Institute of Medical Sciences (PGIMS) in Rohtak recruited another infant.
- Lokmanya Tilak Municipal Medical College in Mumbai was also identified.
Conclusion
NeoSep1 addresses a major evidence gap in newborn treatment, and it may identify safer choices against resistant infections. Prevention, hygiene and antibiotic stewardship remain essential alongside new evidence.